FT Global Pharmaceuticals and Biotechnology Conference 2013
08.00 - 09.00Registration and Refreshments
09.00 - 09.05Opening Remarks from the Chair

Andrew Jack, Pharmaceutical Correspondent, Financial Times

09.05 - 09.30FT View from the Top Opening Keynote Interview

Pascal Soriot, Chief Executive Officer, AstraZeneca in conversation with Andrew Jack

09.30 - 10.30Panel: Buffering the Pharma Brand: Restoring Reputation, Rebuilding Trust

Dr Marijn Dekkers, Chairman of the Board of Directors, Bayer 

William BurnsFormer Chief Executive, Roche Pharmaceuticals and Independent Director on several Boards
Darren CampiliManaging Director, Head of Healthcare Banking EMEADeutsche Bank 
Nikos Dedes, Chair, Positive Voice, Greece & Member of the EMA Management Board 
Rogier Snijdewind, Adviser, Responsible Investment, PGGM Investment 

With recent surveys revealing pharmaceutical companies now ranking in trust perceptions below producers of spirits and tobacco, and physicians basing prescribing decisions as much on brands as on products, the need for pharmaceutical companies to understand and address the factors contributing to poor reputation has never been greater. Brands are the ‘currency’ of life science companies, driving business, enabling them to attract and retain talent, and ensuring they are perceived as partners of choice in today’s increasingly networked healthcare economy. How can pharma companies restore reputation and increase trust? With mistrust of high pricing of drugs and clinical trial results at an all time high, should governments, rather than pharma companies fund research? What role can transparency play? How can social media be harnessed to improve reputation amongst partners and patients? What is the patient’s view of value in pharma?

10:30 - 11:00Networking Coffee Break
11.00 - 11.25Keynote Interview

Professor David Haslam, CBE, Chair, National Institute for Health and Care Excellence (NICE)

11.25 - 12.15The New Pharma Workforce – The Skills to Lead?

Said Darwazah, Chief Executive Officer, Hikma

Jacques Bouwens, Head, Global Healthcare, Russell Reynolds Associates
Dietmar Eidens, Executive Vice President, Human Resources, MerckSerono
Jeremy Levin, Former President and CEO, Teva Pharmaceutical Industries
Professor Paul Workman, Deputy Chief Executive, The Institute of Cancer Research (ICR)

The changing landscape of the industry-the increasing focus on globalisation, on outcomes, on external collaborations, and on building patient centred services and business, for instance- will require a significant shift in the skills base, and leadership qualities required by life science companies if they are to meet the new challenges they face head on. Cross disciplinary skills in research and economics, in data analytics, as well as leadership qualities focussed on the ability to communicate value to the industry’s multiple stakeholders will be at a premium. Are universities preparing people with the right skills and talent for the tasks ahead? How effectively are life science companies recognising the value of diversity and harnessing the talent across their global organisations to develop potential new revenue streams and better understand the aspirations, needs and preferences of their customers? Does the industry have the leadership skills it needs to take the industry forward?

12.15 - 1.35Lunch
13.35 - 14.00Keynote Address

Jörg ReinhardtChairman of the Board of Directors, Novartis

14.00 - 15.00Can the Industry Successfully Capitalise on the Potential of Personalised Medicine?

Daniel O’Day, Chief Operating Officer, Pharmaceuticals, Roche

Edward Abrahams, President, Personalized Medicine Coalition
Stephen Eck, Vice President, Global Head of Medical Oncology, Astellas Pharma Global Development 
Luke Johnson, Chairman, Risk Capital Partners, Chairman, The Institute of Cancer Research (ICR)
Hakan Sakul, Executive Director, Head of Diagnostics Worldwide R&D, Pfizer

Some decade or so since the completion of the human genome project there has been tremendous scientific progress in genomics. However despite the high expectations, it is now considered less likely that genomics will have a major clinical effect on the prognosis of common complex diseases, and despite the identification of numerous gene-drug associations, few have been incorporated into clinical practice. What are the challenges and barriers and how can they be addressed to ensure that the potential of personalised medicine becomes a reality in improving the health outcomes of patients, and a commercial success for life science companies? Do the economics of personalised medicine stack up? 

15.00 - 15.25Keynote Interview: Accelerating Innovation and Collaboration Across Clinical R&D and Healthcare

Jonathan Sheldon, Global Vice President, Health Sciences, Oracle Health Sciences in conversation with Andrew Jack

15.25 - 15.55Networking Coffee Break
15.55 - 16.55The Power of Networks, Partnerships and Alliances - Strategies for Effective R&D Collaboration

Andrew JackPharmaceutical Correspondent, Financial Times

Dr Jean-Paul Kress, President and Chief Executive Officer, Sanofi Pasteur MSD
Dr Denis Lacombe, Director, European Organisation for Research and Treatment of Cancer (EORTC)
Ciaran MurrayChief Executive Officer, ICON plc
Professor Sir John TookeVice Provost (Health), Head of UCL School of Life & Medical Sciences and Head of UCL MedicalSchool, UCL
Timothy WrightGlobal Head, Development , Novartis Pharmaceuticals

In their bid to improve the productivity as well as share the costs and risks of R&D, life science companies are turning to an ever larger and more varied number of collaborations - with academics, not-for-profits, and with CROs - and tapping the ‘wisdom of the crowd’ through crowdsourcing. To be successful, different kinds of collaborations will be needed at different stages of the R&D lifecycle. How are networks evolving? What are the emerging modes for collaboration and to which parts of the lifecycle do they apply? How do you build systems and incentive structures to collaborate effectively? What is the importance of location in the era of increasingly ‘virtual’ networked pharma?
16.55 - 17.45The Transformative Role of Real World Data


Mike Standing, COOMonitor Deloitte Europe


Christopher CorsicoCorporate Senior Vice President, Medicine, Quality, Regulatory, Pharmacovigilance and Epidemiology, Boehringer Ingelheim

Ciarán DevaneChief Executive, Macmillan Cancer Support

Joan DzenowagisSenior Scientist-eHealth, World Health Organization

Dr Lee Newcomer,Senior Vice President, UnitedHealthcare

Dr John Parkinson, Director, Clinical Practice Research Datalink (CPRD)

Vast amount of annoymised healthcare data records are now available either in public systems or in private networks

enabling detailed tracking of how patients are treated in the real world. This creates significant opportunities for pharma for more focused R&D, patient targeting and pricing for outcomes. For hospital systems, this creates an opportunity to build new partnerships with pharma companies to ensure that medical interventions are targeted effectively and can be priced according to outcomes. It enables both pharma and providers to understand how their actions jointly influence patient outcomes, enabling new forms of collaboration. The question is – who is ready for this change in using data to fundamentally change how pharma and the healthcare system interacts?  How fast will this change happen?  What concerns exist? Does the healthcare system trust pharma and vice versa?

17.45 - 17.50Closing Remarks from the Chair and Networking Cocktail Reception

08.15 - 09.00Registration and Refreshments
09.00 - 09.05Opening Remarks from the Chair

Reynold W. (Pete) MooneyGlobal Leader, Life Sciences and Health CareDeloitte
09.05 - 9.30Keynote Address

9:30 - 9:55CEO Interview

Eyal Desheh, Acting President and CEO, Teva Pharmaceutical Industries in conversation with Andrew Jack

9.55 - 10.55Panel: Europe in Crisis - Managing for Uncertainty

Reynold W. (Pete) Mooney, Global Leader, Life Sciences and Health Care, Deloitte

Richard Bergström, Director General, European Association of Pharmaceutical Industries and Associations (EFPIA)
Roberto Gradnik, Chief Executive Officer, Stallergenes, President, European Biopharmaceutical Enterprises (EBE)
Yann Le CamChief Executive Officer, European Organisation for Rare DiseasesEURORDIS
Miklós Szócska, Minister of State for Health, Ministry of Human Resources, Hungary

The ongoing economic crisis and related austerity measures in Europe have been profoundly troubling for the life science industry. As price discounts become the norm across Europe’s troubled economies, life science companies warn that reference pricing, parallel trading and their resultant revenue loss could undermine their ability to carry out R&D and threaten Europe’ s future as a leading centre for innovation. Pharma companies face moral hazard in the current crisis, as failure to supply drugs could risk public opprobrium and threaten their ability to supply the faltering markets as the economy recovers. What is the outlook for Europe’s economies-is there a glimmer of light amidst the gloom? How can life science companies recalibrate their strategies to deal with the current crisis and possible future fallout from fragmentation of the Euro zone? How might the current crisis impact the structure of the life science industry in the longer term? What are the implications forEurope as a market and as a centre for innovation?  

10.55 - 11.15Networking Coffee Break
11:15 - 12:15Unlocking Africa’s Potential

Kofi Amegashie, Managing Executive, Africa, Adcock Ingram Healthcare
Jane GriffithsGroup Chairman, Janssen Europe, Middle East and Africa
John Howe III, President and CEO, Project Hope
Feng Zhao, Health Division Manager, African Development Bank

With strong macroeconomic fundamentals, a shifting disease profile, improved healthcare spending and a rising middle class, Africa is increasingly seen as the frontrunner for life science opportunities in emerging markets. Spending on pharma products across the continent  is set to rise from a current $18bn to $30bn by 2016 and $45bn by 2020 in line with economic growth rates of 10.6% in a large majority of African markets. What are the innovative approaches and strategies life science and healthcare companies are adopting to overcome hurdles (e.g. distribution, health literacy, product safety. pricing) and to build successful and sustainable, businesses and increase patient access in Africa?

12.15 - 12.20Closing Remarks from the Chair